<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain><z:e sem="disease" ids="C1527249,C0009402" disease_type="Neoplastic Process" abbrv="">Colorectal cancer</z:e> is the third leading cause of <z:e sem="disease" ids="C1306459,C0006826" disease_type="Neoplastic Process" abbrv="">cancer</z:e>-related mortality in the world; <z:hpo ids='HP_0011420'>death</z:hpo> usually results from uncontrolled <z:e sem="disease" ids="C0027627" disease_type="Neoplastic Process" abbrv="mets">metastatic disease</z:e> </plain></SENT>
<SENT sid="1" pm="."><plain>Previously, we developed a novel strategy of TNF-related <z:mpath ids='MPATH_3'>apoptosis</z:mpath>-inducing ligand (Apo2L/TRAIL) in combination with <z:hpo ids='HP_0001945'>hyperthermia</z:hpo> to treat hepatic colorectal <z:e sem="disease" ids="C0027627" disease_type="Neoplastic Process" abbrv="mets">metastases</z:e> </plain></SENT>
<SENT sid="2" pm="."><plain>However, previous studies suggest a potential hepatocyte cytotoxicity with TRAIL </plain></SENT>
<SENT sid="3" pm="."><plain>Unlike TRAIL, anti-human TRAIL receptor antibody induces <z:mpath ids='MPATH_3'>apoptosis</z:mpath> without hepatocyte toxicity </plain></SENT>
<SENT sid="4" pm="."><plain>In this study, we evaluated the anti-<z:e sem="disease" ids="C0027651" disease_type="Neoplastic Process" abbrv="">tumor</z:e> efficacy of humanized anti-<z:hpo ids='HP_0011420'>death</z:hpo> receptor 4 (DR4) antibody mapatumumab (Mapa) by comparing it with TRAIL in combination with <z:hpo ids='HP_0001945'>hyperthermia</z:hpo> </plain></SENT>
<SENT sid="5" pm="."><plain>TRAIL, which binds to both DR4 and <z:hpo ids='HP_0011420'>death</z:hpo> receptor 5 (DR5), was approximately tenfold more effective than Mapa in inducing <z:mpath ids='MPATH_3'>apoptosis</z:mpath> </plain></SENT>
<SENT sid="6" pm="."><plain>However, <z:hpo ids='HP_0001945'>hyperthermia</z:hpo> enhances <z:mpath ids='MPATH_3'>apoptosis</z:mpath> induced by either agent </plain></SENT>
<SENT sid="7" pm="."><plain>We observed that the synergistic effect was mediated through elevation of reactive oxygen species, c-Jun N-terminal kinase activation, Bax oligomerization, and translocalization to the mitochondria, loss of <z:hpo ids='HP_0001427'>mitochondrial</z:hpo> membrane potential, release of <z:chebi fb="1" ids="18070">cytochrome c</z:chebi> to cytosol, activation of caspases, and increase in poly(<z:chebi fb="13" ids="16761">ADP</z:chebi>-<z:chebi fb="1" ids="33942">ribose</z:chebi>) polymerase cleavage </plain></SENT>
<SENT sid="8" pm="."><plain>We believe that the successful outcome of this study will support the application of Mapa in combination with <z:hpo ids='HP_0001945'>hyperthermia</z:hpo> to colorectal <z:e sem="disease" ids="C0494165" disease_type="Neoplastic Process" abbrv="">hepatic metastases</z:e> </plain></SENT>
</text></document>